Therapeutic factor XII antibody

US12134657B2 · kind B2 · utility

Assignees

• Oregon Health & Science University · US
• Aronora, Inc. · US

Inventors

• Michael Wallisch · Portland, US
• Andras Gruber · Portland, US
• Erik I. Tucker · Portland, US
• Christina U. Lorentz · Portland, US

Key dates

• Filing date: Nov 27, 2019
• Grant date: Nov 5, 2024
• Expiry date: Feb 17, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.